9 Results

People

  1. Drilon
    Drilon
  2. O'Reilly
    O'Reilly
  3. Schram
    Schram
  4. Chauhan
    Chauhan
  5. Hyman
    Hyman
  6. Ladanyi
    Ladanyi
  7. Shameem
    Shameem
  8. Somwar
    Somwar
  9. Torrisi
    Torrisi
  10. Abida
    Abida

Groups

  1. Center for Pancreatic Cancer Research (9)
  2. Department of Medicine (9)
  3. Gastrointestinal Oncology Service (9)
  4. Gynecologic Medicine Service (9)
  5. Solid Tumor Oncology Division (9)
  6. Thoracic Oncology (9)
  7. Early Drug Development Service (8)
  8. GSK Faculty (3)
  9. Human Oncology and Pathogenesis Program (3)
  10. Sloan Kettering Institute Postdocs (3)
  1. "Department of Medicine"
  2. "Alexander Drilon"
  3. "Eileen O'Reilly"
Formats
  1. Meeting Abstract (7)
  2. Journal Article (2)
Groups
  1. Center for Pancreatic Cancer Research (9)
  2. Department of Medicine (9)
  3. Gastrointestinal Oncology Service (9)
  4. Gynecologic Medicine Service (9)
  5. Solid Tumor Oncology Division (9)
  6. Thoracic Oncology (9)

More Groups

People
  1. Alexander Drilon (9)
  2. Eileen O'Reilly (9)
  3. Alison Schram (8)
  4. Marc Ladanyi (3)
  5. David Hyman (2)
  6. Jean Torrisi (2)

More People

Years
  1. 2023 (1)
  2. 2022 (2)
  3. 2021 (3)
  4. 2020 (1)
  5. 2019 (2)
Publications
  1. Journal of Clinical Oncology (4)
  2. Annals of Oncology (2)
  3. Cancer Discovery (1)
  4. Journal of Thoracic Oncology (1)
  5. Molecular Cancer Therapeutics (1)
Publishers
  1. American Society of Clinical Oncology (4)
  2. American Association for Cancer Research (2)
  3. Oxford University Press (2)
  4. Elsevier Inc. (1)

Results (9)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Schram, A.; Macarulla, T.; Cleary, J.; Neuzillet, C.; Arnold, D.; Reiss, K. A.; Bekaii-Saab, T.; Rodon, J.; Goto, K.; Rha, S. Y.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers
    Meeting Abstract

    Schram, A. M.; Goto, K.; Kim, D. W.; Martin-Romano, P.; Ou, S. H. I.; O'Kane, G. M.; O'Reilly, E. M.; Umemoto, K.; Duruisseaux, M.; Neuzillet, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Zenocutuzumab, a HER2XHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements
    Journal Article

    Schram, A. M.; Odintsov, I.; Espinosa-Cotton, M.; Khodos, I.; Sisso, W. J.; Mattar, M. S.; Lui, A. J. W.; Vojnic, M.; Shameem, S. H.; Chauhan, T.; more...
    Cancer Discovery (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions
    Meeting Abstract

    Schram, A. M.; O'Reilly, E. M.; O'Kane, G. M.; Goto, K.; Kim, D. W.; Neuzillet, C.; Martin-Romano, P.; Duruisseaux, M.; Nagasaka, M.; Rodon, J.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Therapeutic implications of germline testing in patients with advanced cancers
    Journal Article

    Stadler, Z. K.; Maio, A.; Chakravarty, D.; Kemel, Y.; Sheehan, M.; Salo-Mullen, E.; Tkachuk, K.; Fong, C. J.; Nguyen, B.; Erakky, A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase 2 study of zenocutuzumab (MCLA-128), a bispecific HER2/HER3 antibody in NRG1 fusion-positive advanced solid tumors
    Meeting Abstract

    Schram, A.; Macarulla, T.; O'Reilly, E.; Rodon, J.; Wolpin, B.; Ou, S.; Kim, D.; Yang, J. C.; Lam, J.; De Langen, A.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors
    Meeting Abstract

    Schram, A. M.; Drilon, A. E.; Macarulla, T.; O'Reilly, E. M.; Rodon, J.; Wolpin, B. M.; Ou, S. H. I.; Kim, D. W.; Yang, J. C.; Lam, J. Y. C.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
    Meeting Abstract

    Schram, A. M.; O'Reilly, E. M.; Somwar, R.; Benayed, R.; Shameem, S.; Chauhan, T.; Torrisi, J.; Ford, J.; Maussang, D.; Wasserman, E.; more...
    Molecular Cancer Therapeutics (2019)

    Fulltext@MSK | Save
  • A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours
    Meeting Abstract

    Schram, A. M.; Drilon, A.; Macarulla Mercade, T.; O'Reilly, E. M.; Rodon, J. A.; Wolpin, B. M.; Ou, S. H. I.; Kim, D. W.; Yang, J. C. H.; Lam, Y. C. J.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save